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OXIDATIVE STATUS AS A PREDICTOR OF DISEASE ACTIVITY AND 
RESPONSE TO THERAPY IN PEDIATRIC PATIENTS WITH 
INFLAMMATORY BOWEL DISEASE 
ARMAAN F. MAZRA  
ABSTRACT 
INTRODUCTION: Inflammatory Bowel Disease (IBD) is a multifactorial chronic 
relapsing condition thought to be caused by an interplay between a patient’s genetics, 
immune system, and susceptibility to environmental factors. Oxidative Stress (OS) is one 
pathogenic mechanism driving the inflammation and tissue damage observed in patients 
with IBD. OS in IBD is mediated by an overwhelming abundance of reactive oxygen and 
nitrogen species (RONS) generated by activated immune cells, including neutrophils and 
macrophages, that have been recruited to the intestinal mucosa. The relative abundance of 
RONS is assessed using technology capable of directly measuring the ambient oxidative-
reductive potential (ORP) in tissue or a fluid sample. ORP values can provide new 
approaches that link disease pathogenesis with treatment.   ORP assessment may prove to 
be a sensitive, inexpensive, and non-invasive biological marker in the diagnosis and 
interval assessment of patients with IBD. 
OBJECTIVES: The goal of this study was to assess the relationship between disease 
activity and oxidative-reductive potential (ORP) in the stool and urine of patients with 
and without IBD. 
METHODS: Patients admitted to Boston Children’s Hospital (Boston, MA) were 
recruited and consented to participate in this study. Stool and urine samples were 
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collected, and the ORP (mV) was measured using the Arrowdox, PCE, and Redoxsys 
devices. Samples were collected between the period of November 2018 and March 2021. 
RESULTS: The data demonstrate that measuring the ORP of stool supernatants may be a 
useful biomarker for assessing disease activity in patients with IBD. The several phases 
of this study include addressing (1) the accuracy, reliability, and validity of ORP 
measurements in stool and urine (2) establishing methods that provide consistent intra- 
and inter-device readings. These findings ultimately led to the measurement of stool 
supernatant & pellet using the Arrowdox and Redoxsys platforms. Data collected 
demonstrate a relationship between ORP (mV) measurements of stool supernatants and 
increased disease activity in patients with IBD.   
CONCLUSION: The measurement of ORP in the stool of patients with and without IBD 
may be a reliable tool for indicating clinical disease status. Stool supernatant ORP 
readings appear to provide the most consistent intra- and inter-device readings. The 
future of developing this technology study will focus on amplifying patient recruitment to 
more definitively assess the relationship between stool ORP measurement and disease 
activity in patients with and without IBD. Urine ORP values may not reflect disease 
activity in patients with IBD. However, further studies that focus on how urine ORP 
changes over time and under certain conditions (2°C, 20°C, and -80°C) are necessary. A 
more thorough understanding of the impact of diet, gut aerobic and anaerobic bacterial 
makeup, and hematochezia prevalence on redox status is also needed to control for 
potentially confounding variables. The ability to reliably measure redox measurements 
will support clinical trials assessing candidate antioxidant therapies.  
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Inflammatory Bowel Disease: Ulcerative Colitis, Crohn’s Disease, and 
Indeterminate Colitis  
Inflammatory Bowel Disease (IBD) is an overarching umbrella term that 
characterizes three subspecific conditions: Crohn’s Disease (CD), ulcerative colitis (UC), 
and indeterminate colitis (IC). All three forms of IBD manifest as relapsing-remitting 
inflammatory diseases that affect different regions of the gastrointestinal (GI) tract 
(Inflammatory Bowel Disease (IBD) - Symptoms and Causes, n.d.). CD is characterized 
by inflammation present within any part of the digestive tract, from the mouth extending 
to the anus, primarily involving the ileum, cecum, and colon. The full thickness of the 
intestinal wall can be involved in the inflammatory response and extend from the mucosa 
through the serosa (Crohn’s Disease | NIDDK, n.d.). UC is characterized by 
inflammation of the colon (large intestine). The inflammation observed is generally 
confined to mucosa (Colitis, Ulcerative - MeSH - NCBI, n.d.).  IC represents the smallest 
subset (10-15%) of IBD, and these patients manifest radiologic, endoscopic, and 
histologic features consistent with both CD and UC (Guindi & Riddell, 2004). 
 Most patients with IBD are diagnosed during adulthood.  Approximately 20% are 
diagnosed in the first two decades of life. However, the incidence of childhood-onset IBD 
is increasing. Moreover, the prognosis of IBD in pediatric patients differs considerably 
from that observed in their adult counterparts.  The clinical course of IBD in children is 
typically much more aggressive (Moon, 2019). The physiological and developmental 
differences between children and adults must be taken into account when considering 
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treatment options. Also, age-appropriate disease activity indices have been validated for 
use in children with IBD. A few of the indexes used to assess IBD severity in children 
include the Pediatric Ulcerative Colitis Activity Index (PUCAI), Pediatric Crohn’s 
Disease Activity Index (PCDAI), and the Paris Classification of Crohn’s Disease and 
Ulcerative Colitis. The Paris Classification is a modified version of the Montreal 
Classification of IBD and was created to refine the shortcomings in the Montreal’s 










Figure 1. Montreal and Paris Classification of Ulcerative Colitis. The Paris 
Classification of ulcerative colitis is designed for use in pediatric patients with UC. It 
includes an assessment of the macroscopic appearance of the disease, extending from the 




Figure 2. Montreal and Paris Classification of Crohn’s Disease. The Paris 
Classification of Crohn’s Disease is designed for use in pediatric patients with CD. It 
includes a comprehensive assessment of age (A1a, A1b), the location of disease (L4a, 
L4b), as well as behavioral (B2B3) and growth (G0, G1) assessments. (Taken from Levine 
et al., 2011). 
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Pathophysiology of Inflammatory Bowel Disease 
The pathogenesis that drives IBD has not been fully elucidated.  However, it is 
generally recognized to involve a complex interplay between genetics, environmental 
factors, and the body’s innate and adaptive immune systems. Many genetic risk factors 
have been identified, and the DNA loci that explain the clinical expression of IBD 
remains an area of active investigation (Ellinghaus et al., 2015). Environmental factors 
are known to increase susceptibility to IBD, and systematic reviews have demonstrated 
that migrants moving from low prevalence regions to high prevalence regions have a 
similarly increased risk of developing IBD (Ye et al., 2015). Considerable data implicates 
IBD and a dysfunctional immune system. As such, the focus has been placed on 
identifying the relationship between immune cells (including dendritic cells, T helper 
cells, macrophages, etc.) and immune-derived inflammatory mediators in patients with 
IBD. Identifying these inflammatory mediators now allows clinicians to use much more 
targeted treatments (i.e., anti-tumor necrosis factor agents) and the development of novel 
biomarkers.  
The lumen of the gut is home to an extraordinary intestinal commensal flora that 
has been highly adapted to facilitate the digestion of food. Within the lamina propria of 
the intestinal wall reside the immune cells that comprise the gut’s immune system, the 
innate and adaptive sentinels that protect the surface epithelium and prevent pathogenic 
invasion and infection  (Mowat & Agace, 2014). It is thought that IBD could be caused 
by an aberrant immune response directed against the microorganisms that comprise the 
intestine's commensal flora (Geremia et al., 2014). There is a complex and often tenuous 
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balance between immune tolerance and dysregulation, and any disruption of this balance 
may lead to inflammation.  
The immune system is divided into the innate and adaptive immune systems. The 
innate immune system constitutes the first line of defense against pathogenic invasion in 
the gut. In conjunction with a mucous layer and intact epithelial barrier, the innate 
immune system defends the gut partly through the actions of resident dendritic cells and 
macrophages in the lamina propia. Once activated, these cells produce and release pro-
inflammatory cytokines (i.e., IL23, IL17A, and IFN-gamma) that stem from Innate 
Lymphoid Cells (ILC’s) (Geremia et al., 2014).  
Adaptive immunity involves B- and T-cells that coordinate with the innate 
immune system (i.e., antigen-presenting cells) to confer more targeted attacks against 
nonself-antigens and generate immunologic memory (Bonilla & Oettgen, 2010). A 
disproportionately large T-cell response likely contributes to the inflammation observed 
in patients with IBD through the upregulation of cytokines that activate other cells of the 










Figure 3: Adaptive Immune Response in the Gut of IBD Patients. Resident T-cells 
are activated in response to increases in ambient cytokine levels in the mucosa of patients 
with IBD and differentiate into Th1, Th17, and Th2 cells. Th1 cells produce large 
amounts of the pro-inflammatory cytokines, IFN-gamma and TNF-alpha, which activate 
macrophages and trigger apoptosis of epithelial cells. Th2 cells produce IL-13 which 
further induces epithelial cell apoptosis. However, this excessive or dysregulated 
epithelial apoptosis may ultimately jeopardize mucosal barrier function.  Tissue 
degradation similarly occurs through the local release of neutrophil-derived matrix 
metalloproteinases (MMP’s). Th17 cells are involved in the inflammatory response, both 
through the recruitment of neutrophils and by contributing to further epithelial 
degradation through their activation of MMP (Taken from Geremia et al., 2014). 
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Epidemiology of Inflammatory Bowel Disease  
The highest annual incidence and prevalence of IBD (UC and CD) is in Europe, 
followed by North America, Asia, and Southwest Asia, North Africa (Ye et al., 2015). 
Although CD and UC are different diseases and are treated as such, patients with either 
disorder can present with similar symptoms, including diarrhea, fatigue, abdominal pain, 
bloody stool, reduced appetite, and unintended weight loss (Inflammatory Bowel Disease 
(IBD) - Symptoms and Causes, n.d.). Pediatric patients with IBD can manifest several 
extraintestinal symptoms, including poor weight gain, decreased linear growth, delayed 
onset of puberty, and anemia (Rosen et al., 2015). Due to the negative impact of these 
myriad symptoms on their overall quality of life, patients with IBD often experience 
symptoms of depression and anxiety. 
 Many modifiable risk factors for IBD have been identified, including smoking, 
hygiene, and nutrition. Smoking increases the risk factor of developing CD specifically 
by approximately two-fold (Ye et al., 2015). There has been considerable effort to 
develop a uniform pathogenetic model that explains IBD as the result of an aberrant 
upregulation of the gastrointestinal immune system. One such theory is referred to as the 
Hygiene Hypothesis. Proponents of this theory advocate that it’s the relative lack of 
exposure to bacteria, pathogens, and microbes at a young age that makes individuals in 
Western societies more susceptible to aberrant or exaggerated  immunological reactions 
later in life. Patients with CD are more likely to live with fewer siblings, and the 
prevalence of IBD (UC, CD) is much higher in urban environments (Ye et al., 2015). 
These realities provide insight into why a lack of exposure to environmental pathogens in 
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relatively sterile residential urban environments might make a highly evolved, yet 
hygienically obviated, mucosal immune system respond in such a robust fashion to 
known or perceived intestinal threats. Because IBD primarily impacts the gastrointestinal 
system, nutritional absorption may be impaired during periods of increased disease 
activity.    
Dietary norms vary across cultures, with individuals in particular demographics 
consuming foods with higher/lower concentrations of micronutrients, proteins, 
carbohydrates, fats, antioxidants, and fiber. Due to the difficulty in pinpointing an 
exposure to any individual food or food-type in the onset of IBD, recent emphasis has 
been placed on understanding the impact of varied dietary patterns on the development of 
IBD and other chronic diseases. There is a higher incidence and prevalence of IBD in 
Westernized countries. The Western Diet, viewed relative to Mediterranean and Asian 
diets, consists of higher amounts of refined carbohydrates, saturated fats, industrialized 
food-products, and a lower quantity of raw-foods, vegetables, and fruits. The Western 
diet is low in nutrients with anti-inflammatory and anti-oxidant properties, which may 






Figure 4: Mediterranean Diet vs. Western Diet. This figure outlines the differences in 
food consumption in Western and Mediterranean countries. Taken from (Rizzello et al., 
2019). 
 
Common Treatment Strategies used in Inflammatory Bowel Disease  
 There is currently no cure for IBD.  However, many medical treatments are 
available that can control disease activity.  Decisions about which medication to use are 
typically based on disease type (UC, CD, IC), location, and severity. IBD is a relapsing 
and remitting condition.  As such, treatment is focused on decreasing the incidence and 
severity of interval flares in disease activity. IBD medical therapies consist of biologics, 
immunomodulators, anti-inflammatory agents, and corticosteroids.  
5-aminosalicylic acid (5-ASA) and corticosteroids are often used as first-line 
treatments for newly diagnosed patients with IBD or those experiencing an acute increase 
in clinical disease activity (van Hogezand, 1994). Vitamin D deficiency is very common 
 
11 
and may affect up to 30-40% of children and adults with IBD (Gubatan & Moss, 2018). 
Vitamin D is essential for maintaining bone health. However, there is a growing body of 
data demonstrating its importance in developing and maintaining the immune system. 
Vitamin D has immunomodulatory properties and can decrease inflammation by 
suppressing T-cell activation (Reich et al., 2014). The clinical effectiveness of Vitamin D 
monotherapy as a treatment strategy for IBD is inconclusive.  Nonetheless, 
supplementation can help to regulate normal physiological bone growth and function. 
Immunomodulators (including azathioprine, 6-mercaptopurine, and methotrexate) are 
often prescribed in patients with IBD to help suppress increased immune responses. 
Lastly, anti-TNF agents (including the monoclonals infliximab and adalimumab) are 
biologics that induce and maintain clinical remission in patients with IBD by neutralizing 
the pro-inflammatory cytokine Tumor Necrosis Factor alpha (TNF-alpha) (Carroll et al., 
2019).  
Changes in diet and nutrition can be used as a principal treatment strategy by 
clinicians to treat patients with IBD. The Western diet is believed to impact the 
composition of the intestinal microflora negatively. Therefore, nutritional interventions 
aim to change the type, number, and distribution of species within the microflora. Many 
patients with Crohn’s disease can be treated successfully with exclusive enteral nutrition 
(EEN), partial enteral nutrition (PEN), and Crohn’s Disease exclusive diets (CDED) 
(Verburgt et al., 2021). The EEN diet is a 6-to-12-week treatment strategy that typically 
involves liquid nutritional supplementation delivered orally or through a nasogastric tube. 
These diets are believed to work by altering the composition of the gut flora (Carroll et 
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al., 2019).  Poor tolerance of liquid supplementation or nasogastric tube requisite for EEN 
has led to experimentation with whole-food diets, including PEN and CDED.  These diets 
are less restrictive, much better tolerated, and can induce remission by driving 
comparable changes in the gut microbiome (Levine et al., 2019).   
 
Biomarkers: Fecal Calprotectin (FC), Serum C-Reactive Protein (CRP), 
Erythrocyte Sedimentation Rate (ESR), and Lactoferrin.  
 Biomarkers are objective and measurable indicators of biological states. They can 
help in the diagnosis and interval assessment of patients with a range of disorders. The 
ideal biomarker should be non-invasive, sensitive, specific, and cost-effective.  There are 
no serologic or fecal biomarkers that reliably diagnose or differentiate between particular 
forms of IBD (Chen et al., 2020).  The biomarkers most commonly used in assessing 
patients with IBD include fecal calprotectin (FC) and lactoferrin as well as serum C-
Reactive Protein (CRP) and ESR (erythrocyte sedimentation rate).  
C-Reactive Protein (CRP) is a protein produced by hepatocytes when stimulated by 
cytokines such as IL-6, TNF-alpha, interleukin-1, and IL-1B (Chen et al., 2020). CRP is a 
good indicator of acute inflammation and helps identify patients experiencing increases 
in underlying disease activity. Usually, the CRP concentration in the blood is <1mg/L, 
but during active inflammation, this may increase to over 1,000mg/L. Patients in 
remission typically have a CRP level of less than 10mg/L (Chen et al., 2020). 
Unfortunately, CRP is a non-specific marker of inflammation and, therefore, not useful in 
distinguishing which type of IBD (UC or CD) a patient might have. Furthermore, CRP 
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has low sensitivity, as patients with active disease may also have low CRP levels (Chen 
et al., 2020).  Therefore, CRP may not be the best indicator of intestinal inflammation.  
Fecal calprotectin (FC) is a better marker for distinguishing IBD from non-
inflammatory conditions such as IBS. It has the added benefit of being measured through 
ELISA, making it low-cost and non-invasive. FC makes up about 60% of the protein 
content of neutrophil granules, and its level in the stool is proportional to the degree of 
gut inflammation. However, because an influx of activated neutrophils occurs in many 
different inflammatory GI disorders, FC cannot discriminate between particular 
conditions. Nevertheless, a recent study has shown that an FC level of greater than 
250µg/g had a sensitivity of 71% and a specificity of 100% in detecting endoscopically 
active UC, thereby showing a substantial negative predictive value (Sipponen & Kolho, 
2015).  
The erythrocyte sedimentation rate (ESR) measures the rate at which red blood cells 
fall (or sediment) when placed in a vertical tube (Johnson, 2010). It is often used as 
another proxy marker of inflammation.  However, like CRP, ESR levels don’t distinguish 
between different types of inflammatory diseases, such as Crohn’s disease and UC 
(Menees et al., 2015).   
Lactoferrin is a glycoprotein that, like calprotectin, arises from neutrophil granules 
and is released into the gut lumen after neutrophil degranulation (Stragier & Assche, 
2013). Fecal lactoferrin levels are correlated with intestinal inflammation. It is thought 
that a large number of activated neutrophils transmigrate into the intestinal mucosa 
during the inflammatory response.  These neutrophils release lactoferrin, which passes 
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through the mucosal membrane and into the feces. Concentrations of lactoferrin are 
significantly higher in patients with IBD (UC, CD) in contrast to patients with IBS or 
healthy controls, making it sensitive, specific, and a useful biomarker for distinguishing 
between inflammatory GI conditions from those with IBS (Stragier & Assche, 2013).  
 
Immune System and Oxidative Stress 
 Oxidative stress (OS) is defined as a relative excess of physiological oxidants 
relative to available ambient antioxidants.  As such, the imbalance can result from 
either/both a preponderance of oxidant species or a deficiency in counter-regulatory 
antioxidants (Clinical Relevance of Biomarkers of Oxidative Stress | Antioxidants & 
Redox Signaling, n.d.). In general, OS results from an overwhelming majority of reactive 
oxygen species (ROS), including related reactive nitrogen species (RNS).  These ROS 
can damage intra and extracellular macromolecules through post-translational and 
transcriptional modifications, damage to cellular DNA, and the oxidization of electron-
rich cell membrane lipids, resulting in lipid peroxidation (LP) (Wang et al., 2020). 
Overtime, ROS-mediated damage can result in large-scale macroscopic lesions in the 
intestinal mucosa. It is thought that ROS status could impact disease activity in patients 
with IBD.  However, it remains unclear whether the observed excess ROS serves as a 
precipitant or a consequence of intestinal inflammation.   
The composition and activity of the intestinal microbiota and variabilities in 
immune responses likely contribute to the pathogenesis of IBD. The influx of neutrophils 
and macrophages recruited to the inflamed area release RONS, perpetuating 
inflammation and mucosal damage (Wang et al., 2020).  The increases in RONS likely 
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disrupts the delicate homeostasis existing between the intestinal mucosal immune system, 
the gut commensal flora, and microbes and pathogens. Increased intestinal permeability 
and disruption can lead to a pathogenic invasion, thereby enhancing the immune response 
and subsequent oxidative stress (Wang et al., 2020). 
 It is essential to understand that while ROS are detrimental in excess, they are 
essential components of cellular oxidative metabolism and intracellular signaling (Stagos 
et al., 2015). Common ROS include oxide (O2-) and hydroxyl radicals (OH.), and 
hydrogen peroxide (H2O2).  ROS mediate tissue damage due to their molecular reactivity, 
mediated by unpaired electron shells (Stagos et al., 2015; Wang et al., 2020).  Common 
RNS, which share similar reactive properties of ROS, include nitric oxide (NO), nitrogen 
dioxide (.NO2), and peroxynitrite (ONOO-) (Wang et al., 2020). Besides arising from the 
mitochondria, RONS are often produced through reactions involving the enzymes 
Xanthine Oxidase (XO), Myeloperoxidase (MPO), and Nitric Oxide Synthase (NOS). 
(Clinical Relevance of Biomarkers of Oxidative Stress | Antioxidants & Redox Signaling, 
n.d.; Wang et al., 2020).  XO catalyzes the production of uric acid.  However, it can also 
produce oxygen radicals. MPO catalyzes the reaction between hydrogen peroxide and 
chloride ions to produce the potent ROS HOCl (Clinical Relevance of Biomarkers of 
Oxidative Stress | Antioxidants & Redox Signaling, n.d.).  Lastly, NOS is involved in the 
endogenous generation of NO, which is helps to regulate vascular tone, but can also 





Figure 5: The Role of RONS in Inflammation. This figure provides a very brief 
overview of the role of RONS. Xanthine Oxidase (XO), Myeloperoxidase (MPO), and 
Nitric Oxide Synthase (NOS) are a few of the enzymes responsible for the creation of 
RONS. RONS mediators may increase the transcription of inflammatory genes by 
activating the proinflammatory transcription factor NF-kB, counter-regulatory 
antioxidant signaling pathways (NRF2), and the induction of autophagy (TFEB regulated 
pathway).  Adapted from (Clinical Relevance of Biomarkers of Oxidative Stress | 






As previously mentioned, the relative excess of RONS contributes to the 
development of the intestinal lesions commonly seen in IBD. In response, the body has 
evolved highly adapted strategies to mediate enzymatic and non-enzymatic defensive 
antioxidants. These include Superoxide Dismutase (SOD) and Glutathione Peroxidase 
(GP).  Both enzymes are found in tissues throughout the body to check RONS-mediated 
damage (Wang et al., 2020). In addition, non-enzymatic antioxidants consist of 
glutathione, thioredoxin, and Nrf2. Glutathione and thioredoxin are ROS scavengers and 
involved in electron acceptation/donation (Wang et al., 2020). Nrf2 (nuclear factor 
erythroid 2-related factor 2) is an important transcription factor involved in the counter-
regulation of redox status.  While typically sequestered in the cytoplasm by binding to 
Keap1, redox imbalance dissociates Nrf2 from this cytoplasmic anchor. It can 
subsequently gain entrance to the nucleus, where it mediates the synthesis of antioxidant 
gene products, including the enzymes glutathione S-transferase (GST) and superoxide 
dismutase (SOD).  Interestingly, it has been noted that Nrf2 levels are decreased in UC 
subjects (Piotrowska et al., 2021).   
Furthermore, exogenous dietary antioxidants can also play a vital role in oxidative 
regulation. If OS results from a relative imbalance between oxidative and anti-oxidative 
species, supplementation with exogenous (dietary) anti-oxidants could present a novel 
adjunct approach to existing therapies (Wang et al., 2020). This approach would benefit 
from being relatively inexpensive, generally well-tolerated, and eliminate or reduce a 
reliance on potentially toxic immunosuppressive therapies (Moura et al., 2015). 
Exogenous antioxidants may counter the effects of RONS by acting as direct RONS 
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scavengers (like Glutathione and Thioredoxin), decreasing enzymatic production of 
RONS, and increasing the enzymatic degradation of RONS (Khan et al., 2017). A few 
drug-based antioxidant therapies include allopurinol and 5-amino salicylic acid (5-ASA). 
Allopurinol is used as an adjunct therapy that helps enhance immunosuppression, and in-
vitro and in-vivo studies have demonstrated the RONS scavenging capabilities of 5-ASA 
(Balmus et al., 2016; Khan et al., 2017). The antioxidant efficacy of molecules 
chemically-derived from food and nutrient sources has been studied in turmeric, red 
grapes, berries, peanuts, and many other vegetable sources (Khan et al., 2017; Moura et 
al., 2015). The net impact of dietary antioxidants may be limited by bioavailability, rapid 
absorption, or kinetic constraints. Most dietary and synthetic compounds have been 
derived from polyphenols, a class of naturally occurring molecules that act as RONS 
scavengers, interact with redox signaling proteins, and inhibit the NF-kB inflammatory 
cascade (Moura et al., 2015). For example, curcumin, which is the antioxidant present in 
turmeric, has been implicated in decreasing the activity of the aryl hydrocarbon receptor, 
COX, and IL-1B, which are all involved in inflammatory responses (Khan et al., 2017). 
The effects of curcumin are increased when taken in combination with mesalamine or 
other plant-based antioxidants (Khan et al., 2017; Moura et al., 2015).  Resveratrol, 
which is present in red grapes and berries, interacts with NF-kB, and COX1 and COX2 
enzymes (Moura et al., 2015). Lastly, Quercetin, abundant in many fruits and vegetables, 
attenuates OS through its effect as a RONS scavenger and GSH modulator. Quercetin 
also promotes the intestinal barrier function by promoting tight junction assembly in the 
intestinal epithelia (Moura et al., 2015).  
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Specific Aims and Objectives 
There is an increasing need to develop informative clinical biomarkers for use in 
the diagnosis and interval assessment of patients with Inflammatory Bowel Disease 
(IBD). Current IBD biomarkers are not uniformly specific, predictive, and reflective of 
clinical or mucosal disease activity (Clinical Relevance of Biomarkers of Oxidative Stress 
| Antioxidants & Redox Signaling, n.d.). As a result, clinicians now rely on endoscopic 
examination to assess response to therapy or the development of disease exacerbation or 
complication. These procedures are expensive, invasive, and morbid.   
Given the relationship between RONS and potential tissue damage, this study's 
primary objective is to directly measure the ambient ROS status within the gut mucosa 
using biological fecal samples. Due to challenges related to the assessment of individual 
RONS species, the Oxidation Reduction Potential (ORP) was used to assess OS in IBD. 
The ORP is an integrated measure of the balance between total oxidants and antioxidants 
present within a medium (Stagos et al., 2015). Assessment of the ORP will help to 
elucidate the relative role played by RONS in areas of mucosal inflammation. We 
hypothesize that the chronic inflammatory disease observed in patients with IBD and its 
association with oxidative species will result in significant differences in ORP (mV) 
measurements of fecal samples collected from patients with and without active IBD.   
The analysis will be extended to include the measurement of ORP in other 
biological samples, including urine, blood, and intestinal aspirates. Furthermore, a 
comparison of oxidant status and contemporaneous biochemical inflammation measures, 
including erythrocyte sedimentation rate and CRP, will be conducted. As a result, data 
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from this study should further the development of standardized assays to measure the 
relationship between RRS, disease prognosis, and response to therapy. This technology 
should also enable a more rational assessment of the response and efficacy of anti-




















Experimental Design  
This project is a prospective cohort study of children admitted to Boston Children’s 
Hospital. Approval was received from the Institutional Review Board (IRB) to approach 
all admitted patients and enroll those who agreed to participate by signing a consent form 
detailing the study’s parameters.  
 
Reduction-Oxidation (Redox) Measurement Devices 
Three different redox measurement devices and probes were used to measure stool and 
urine samples’ redox values.   
 The Advanced Micro Oxidation-Reduction Measurement System (Arrowdox) 
is made by the Shelfscientific Division of Lazar Research Laboratories Inc. Samples were 
measured using a Model ORP-146S micro combination redox 1mm electrode, which can 
measure RRS in microvolume samples as small as 5µL. The probe contains a filling 
solution of potassium chloride. Air bubbles were removed to ensure continuous current 
flow and consistent readings. Before use, the electrode sensor was dipped into a solution 
containing 5 M HNO3 for 30 seconds and rinsed with liberal amounts of DI water. The 
sensor was then submerged in Biotrue multi-purpose solution from Bausch & Lomb to 
clean, disinfect, and rinse proteins and particulates. The probe was then re-rinsed with DI 
water and wiped dry with a lab paper wipe to eliminate the possibility of solution 
carryover. The probe was finally connected to an electrometer, Lazar Model 6230 




 PCE ORP-14 is a redox electrode made by PCE instruments. The device came 
prefilled with a potassium chloride solution. The PCE probe was cleaned using Biotrue 
for 30 seconds and thoroughly rinsed with distilled water prior to use. The PCE probe 
was then connected to the PCE-228-R meter (Ajithkumar, 2020; Weinbren, 2019).  
Redoxsys Diagnostic System is a product of Aytu Biosciences. The Redoxsys 
Diagnostic System used single-use Redoxsys sensors onto which 30µL of the liquid 
sample was placed. Upon inserting the sensor into the Redoxsys, the ORP of the sample 
was provided in approximately 3-5 minutes (Ajithkumar, 2020; Weinbren, 2019).  
 
Patient Population Selection  
All patients admitted to Boston Children’s Hospital were eligible for participation 
in the study. During Phase One of the study, patients were eligible for participation if 
they were admitted to Boston Children’s Hospital under the Gastroenterology Service. 
Expanded recruitment guidelines then allowed for any admitted patient to be a part of the 
study. Recruitment of samples was carried out during a period extending from November 
2018 to March 2021. Staggered recruitment was related to efforts in developing optimal 
storage and performance study conditions. There were no exclusion criteria for pediatric 
and adolescent patients in this pilot study (Ajithkumar, 2020; Weinbren, 2019). 
Phase One: During the initial phase of this study, progress was limited by the availability 
of stool samples. Initial conditions were restricted to studying only 
fresh/unstored/unrefrigerated samples. Immediate sample collection and measurement 




ORP might change with time. Therefore, admitted patients were consented to the study 
only if they had stool samples available for immediate collection. During this phase, 
patient samples were rejected if they were more than 1-2 hours old. (Ajithkumar, 2020; 
Weinbren, 2019).  
Phase Two: The second phase of sample collection was conducted after establishing 
optimal experimental benchmarks and storage conditions for stool ORP (Ajithkumar, 
2020; Weinbren, 2019). Admitted patients were approached and consented to the study 
regardless of the ability to immediately provide a stool sample. Patients were provided a 
collection kit consisting of a specimen collection bag, collection hat, and sample 
collection cup. After the patient provided the stool sample, a member of the patient’s care 
team placed the sample in a refrigerator and notified a member of the research team. 
Established optimal experimental benchmarks permitted ORP measurement within 24 
hours of stool collection (Ajithkumar, 2020).  
Phase Three: The first two phases consisted of solely stool collection and measurement. 
During Phase Three, urine samples were collected and assayed similarly to Phase Two 
using the Arrowdox and Redoxsys platforms. Furthermore, to obtain consistent intra- and 
inter-device readings, measurement techniques were further optimized.  
Phase Four: This phase entails establishing standardized procedures in collecting and 
measuring blood samples. Moreover, standardized techniques in the measurement of the 
ORP of intestinal aspirates will be established. Intestinal aspirates will be collected from 
patients undergoing scheduled endoscopic procedures in the Gastrointestinal Procedure 






Figure 6. ORP of Standard Solution using the Arrowdox, PCE, and Redoxsys. 
Average readings of the ZoBell’s Standard, Standard A, and Standard B were used to test 
the internal validity of measurements taken by the Arrowdox, Redoxsys, and PCE 
devices. All three probes gave readings within 5-10 mV of the expected values. ZoBell’s: 
223-233mV; Standard A: 240mV; Standard B: 468mV (Ajithkumar, 2020; Weinbren, 
2019). 
Initial Measurements:  
The accuracy and reliability of ORP measurements taken by the Arrowdox, 



























6. Standard A and Standard B, from PCE InstrumentsTM, were calibrated to 240 mV and 
468 mV, respectively (Weinbren, 2019). The ZoBell’s ORP Standard, from Hach 
Company, was calibrated to 223-233mV. Furthermore, the internal validity of the devices 
was tested through ORP measurements of 1:2 dilutions of juices, measured for their 
antioxidant properties, and H2O2, measured for it’s oxidative capacity (Figure 8). 
  
Patient Sample Measurements  
All patient samples were measured three times. Every week, probes were re-
calibrated using commercial standard solutions to ensure accurate readings were being 
obtained. During the first phase of the study, the Arrowdox and PCE platforms were 
used to measure the ORP of stool samples. The Redoxsys was unavailable for use at this 
time. The reliability of ORP measurements at the 24-hour mark was established by 
measuring the ORP of stool samples at 0, 2, 4, 6-, 8-, 24-, and 48-hour intervals under 
frozen (-80°C), room (20°C), and refrigerated (2°C) temperatures (Weinbren, 2019). 
After determining that ORP remained consistent under these conditions, measurements 
were taken as outlined in the second phase of the study.  
During the second phase of the study, the Redoxsys system was added as a 
device used to measure the ORP of stool samples. However, because particulate matter 
interferes with the Redoxsys sensors, only liquid samples can be measured using this 
platform. Therefore, 30µL of stool supernatant was pipetted onto the Redoxsys sensor. 
Stool supernatant was obtained by spinning native stool at 12000 rpm for 5 minutes 




The third phase of the study consisted of implementing urine analysis and 
establishing further efforts to achieve standardized and optimal measurement conditions. 
The Redoxsys and Arrowdox platforms proved to be the most reliable instruments for 
stool supernatant measurement. Samples were prepared by spinning an aliquot of stool 
homogenate at 7000rpm for 15 minutes. If the stool's consistency was formed, the the 
sample was first diluted with 0.5µL of distilled water, modified from (Million & Raoult, 
2018). A stool homogenate was obtained by thoroughly stirring samples using a wooden 
tongue depressor until the color and consistency were uniform. The ORP of the stool 
pellet was also measured. Urine samples were obtained in a fashion similar to stool 
sample collection, and refrigerated (2°C) samples were measured at an interval between 
8-hours and 24-hours post-production. Real-time sample measurement was performed 
whenever possible.   
Patient-specific data were obtained through abstraction from the electronic 
medical records and stored on Microsoft Excel spreadsheets under password protection 
and behind the BCH digital firewall. Patient consent forms were completed during patient 
enrollment and filed in a locked location in the Center for Inflammatory Bowel Disease. 
Consent forms were then scanned and uploaded to the Children’s Hospital Electronic 
Research Portal (CHeRP). To maintain patient confidentiality, patients were assigned 
study identification numbers (i.e., Patient 1, 2, n...) (Ajithkumar, 2020; Weinbren, 2019).   
The Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric 
Crohn’s Disease Activity Index (PCDAI) were used to measure patient disease status. 




obtained from the electronic medical record. These data can be used to stratify patients by 
disease activity and response to therapy (Weinbren, 2019).  
Table 1 reflects the grading for the PUCAI. These scores consider six categories 
of active UC diagnosis: abdominal pain, rectal bleeding, stool consistency, number of 
stools per day, nocturnal activity, and relative activity. PUCAI scores range from 0-85, 
and active disease is defined as a score >10 (Weinbren, 2019).  
 Table 2 reflects the grading for the PCDAI. It considers a patients’ history of 
abdominal pain, stool, general function & well-being, laboratory values, and physical 
examination values. PCDAI scores range from 0-100, and active Crohn’s Disease is 
defined as a PCDAI score of >11 (Weinbren, 2019).   
 
Statistical Analyses: 
Data analysis for the phase one time-measurement stool ORP analysis was 
conducted using a t-test (hypothesized mean difference: 0, alpha=0.05). Data analyses for 
mean ORP differences between IBD-groups (UC, CD, IC) and Controls were conducted 









Table 1. The Pediatric Ulcerative Colitis Activity Indexa 
 
                          Item                          Points 
  Abdominal Pain 
No Pain 0 
Pain can be ignored 5 
Pain cannot be ignored                         10 
  Rectal Bleeding 
None 0 
Small amount only in <50% of stool                         10 
Small amount with most stools                         20 
Large amount (>50% of stool content)                         30 
  Stool Consistency of Most Stools 
Formed 0 
Partially formed 5 
Completely unformed                         10 
  Number of Stools Per 24 Hours 
0-2 0 
3-5 5 
6-8                         10 
>8                         15 
  Nocturnal Stools (Any Episode Causing Waking) 
No 0 
Yes                         10 
  Activity Level 
No limitation of activity 0 
Occasional limitation of activity 5 
Severely restricted activity                         10 
Total Maximum Score                         85 
                        Total Sum:  
aThis table shows the criteria and scoring system used by clinicians to generate a metric 







Table 2. The Pediatric Crohn’s Disease Activity Indexa 
 
                                  Item                 Points 
History (Recall, 1 Week) 
  Abdominal Pain 
None 0 
Mild/brief/does not interfere with activities 5 
Moderate/severe/daily, longer-lasting, affects 
activities, nocturnal 
                    10 
  Stools (Per Day) 
No limitation of activities/well 0 
Occasional difficulty in maintaining age-appropriate 
activities/below par 
5 
Frequent limitation of activity/very poor                     10 
  Patient Functioning, General Well-Being 
0-1 liquid stools, no blood 0 
Up to 2 semiformed with small blood, or 2-5 liquid 5 
Gross bleeding, or >5 liquid, or nocturnal diarrhea                     10 
Laboratory 
  Hematocrit 
<10 (Male/Female) 11-14 (Male) 11-19 (Female) 15-19 (Male) 
>33% 0 >34% 0 >33% 0 >36% 0 
28%-32%      2.5 30%-34%      2.5 29%-33%      2.5 32%-36%      2.5 
<28% 5 <30% 5 <29% 5 <32% 5 
  Erythrocyte Sedimentation Rate 
<20 mm/hr 0 




>50 mm/hr 5 
  Albumin 
>3.4 g/dL 0 
3.1-3.4 g/dL 5 
<3.1 g/dL                     10 
Examination 
  Weight 
Weight gain or voluntary weight stable/loss 0 
Involuntary weight stable/weight loss 1%-9% 5 
Weight loss > 10%                     10 
  Height 
<1 channel decrease 0 
>1, <2 channel decrease 5 
>2 channel decrease                     10 
  Height at Follow-Up Visit 
Height velocity > 1 SD 0 
Heigh velocity < 1 SD > 2 SD 5 
Heigh Velocity < 2 SD                     10 
  Abdominal Exam 
No tenderness, no mass 0 
Tenderness or mass without tenderness 5 
Tenderness involuntary guarding, definite mass                     10 
  Perirectal Disease 




aThis table shows the criteria and scoring system used by clinicians to generate a metric 

















1-2 indolent fistula, scant drainage, no tenderness 5 
Active fistula, drainage, tenderness, or abscess                     10 
Extraintestinal Manifestations 




>2                     10 
Total Score Possible                   110 






From November 2018 to March 2021, forty-seven patients were enrolled in the 
Redox study. Of these patients, thirty-five were diagnosed with IBD and were admitted to 
Boston Children’s Hospital for the management of an active-flare state: fourteen of these 
patients were managed for active Crohn’s Disease (CD), nineteen for active Ulcerative 
Colitis (UC), and two for active Indeterminate Colitis (IC). Twelve patients were 
admitted to Boston Children’s Hospital for conditions unrelated to IBD, thus serving as 
controls. Of these twelve, five were admitted for non-GI-related conditions and seven for 
GI-related conditions. Figure 7 displays a flow-chart representing enrollment data. Data 
for patients 33 and 36 were not included as these patients were discharged before samples 
could be collected. 
 The study’s eligibility criteria included any patient admitted to Boston Children’s 
Hospital under medical management for GI and non-GI conditions. These criteria 
allowed for RRS comparisons between samples collected from patients with IBD (UC, 








Figure 7: Flowchart of Patient Enrollment into the Redox Study. A total of forty-
seven patients, with and without IBD, were enrolled in the study beginning November 







The Reliability of Oxidation-Reduction Potential (ORP) Measurements in Native 
(Homogenate) Stool Samples  
Before the first phase of patient enrollment (November 2018 – June 2019), the 
establishment of proper experimental conditions to measure the ORP reliably was 
derived. The relative accuracy and reliability of the PCE and Arrowdox probes were 
tested by measuring the ORP of hydrogen peroxide, apple, orange, and cranberry juice 
dilutions, as shown in Figure 8. These solutions were measured because of their reported 
anti-oxidant values (Weinbren, 2020; Jie Sun et al., 2002). The concentration of redox 
reactants is directly proportional to voltage; increasing concentrations produce higher mV 
values (Million & Raoult, 2018; Stagos et al., 2015). Diluting antioxidant-rich juices 
increased mV readings. Furthermore, diluting H2O2, measured for its high oxidative 
capacity, decreased mV readings. Unexpectedly, H2O2 readings produced higher mV 
readings at 1:8 dilution (Weinbren, 2019).  
After confirming that increasing concentrations of RONS species produce higher mV 
readings, the next step entailed determining whether the ORP of stool had to be measured 
after collection and in real-time. This was completed to ensure the most accurate and 
reliable measurement of stool ORP, as there was no previous literature outlining the 
change of stool ORP over time. The ORP of native stool was measured at 0, 2-, 4-, 6-, 8-, 
12-, 24-, and 48- hour intervals to determine ORP values' reliability over time, as shown 
in Figure 9. The experiment was reconducted using a single patient’s stool sample in 




and frozen (-80°C) temperatures, shown in Figure 10. No significant difference in 
refrigerated stool ORP from t=0 to t=24 hours (p= 0.55) was observed. It was established 
that stool ORP could be reliably obtained between 8- and 24-hours under refrigerated 
(2°C) conditions. This streamlined future patient enrollment as patient samples could be 
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Figure 8: Oxidant-Rich Juice Dilution Curves. Serial dilutions (1:2) were 
made 1:2 in distilled water. Arrowdox and PCE probes were used to generate 
data for these dilution curves. The sources were: a) Cranberry Juice, b) Orange 







Figure 9: The ORP of Refrigerated Native Stool Over Time. The ORP of stool 
homogenate was obtained under 0, 2-, 4-, 6-, 8-, 12-, 24-, and 48- hour intervals under 
Refrigerated (2°C) temperature. No significant change in ORP from t=0 hours to t=24 
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Figure 10: The ORP of Native (Unspun) and Spun Stool Over Time. This figure 
outlines data collected from an experiment similar to Figure 9 conducted in November 
2020. A single patient stool sample was measured. Outlined is the time-change in native 
(unspun) and spun (supernatant) stool ORP (mV) under room (2°C) and frozen (-80°C) 
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ORP of IBD vs. Non-IBD Using Native (Homogenate) Stool  
The second phase of the study included seventeen additional patients (Patients 8-
24) diagnosed with UC, CD, IC, and non-IBD Controls. Stool homogenates were 
measured using the Arrowdox and PCE platforms according to the protocols established 
during the study's first phase. The collected samples were refrigerated between 8- and 24-
hours before measurement. Three measurements were obtained using both of these 
devices. The mean of these three readings was plotted for the homogenate stool samples 
obtained from patients 1-24 in Figure 11 and quantitatively represented for the Arrowdox 
device in Table 3. Note that Patient 15 provided two samples on two different dates, 
indicated as 15-I, 15-II. Furthermore, a Redoxsys measurement was taken if the stool 
samples were liquid enough to be read by the Redoxsys sensor. The mean Arrowdox 
ORP comparing IBD and non-IBD groups was calculated and presented in Figure 12. 
It has been previously shown that fecal samples expected to have increased 
concentrations of RONS (patients presumed to be experiencing more significant 
oxidative stress) produce mV readings more positive in comparison to fecal samples 
obtained from patients that are expected to have decreased concentrations of RONS 
(Million & Raoult, 2018; Stagos et al., 2015). Therefore, it was expected that ORP (mV) 
measurements would be more positive for samples collected from patients with IBD (CD, 
UC, IC) in comparison to control patients. The expected relationship was not observed in 




in the Redox Potential (ORP) from the UC, CD, and IC groups compared to the control 












Figure 11: The ORP of Native Stool. This figure includes Arrowdox and PCE measured 
ORP(mV) of stool samples collected from twenty-four patients with IBD and non-IBD 
related conditions. All values are an average of three trials. The Redoxsys was used for 
samples liquid enough to obtain a reading. Patients are numbered using the notation 
Patient # (Disease; PCDAI/PCUAI). All readings were obtained from samples stored at 



























Table 3. ORP (mV) of Native Stool and Patient Diagnosesa 
Patient (Disease; PUCAI/PCDAI) Arrowdox 
Patient 1 (UC;10) 182 
Patient 2 (UC;45) -480 
Patient 3 (UC; N/A) -533 
Patient 5 (UC;20) 30 
Patient 8 (UC; 15) -268.666667 
Patient 11 (UC; 30) -134 
Patient 13 (UC; 50) 55 
Patient 14 (UC; 30) -118.333333 
Patient 15-I (UC; 20) 62 
Patient 16 (UC;15) -466.333333 
Patient 19 (UC;30) 335 
Patient 21 (UC;65) 116.3333333 
Patient 22 (UC;10) -63.3333333 
Patient 23 (UC;25) 78.66666667 
Patient 15-II (UC;35) 205.6666667 
Patient 4 (CD; N/A) -517 
Patient 6 (CD; 15) -375 
Patient 9 (CD; N/A) -85.3333333 
Patient 17 (CD;30) -61 
Patient 18 (CD;0) -11.6666667 
Patient 20 (CD;10) -12.6666667 
Patient 24 (CD;5) -117.333333 
Patient 12 (IC; 30) -87 
Patient 10 (Control; N/A) -58.3333333 
Patient 7 (Control; N/A) 244 
aThis table lists the average ORP of native (homogenate) stool samples obtained from 







Figure 12: Mean ORP of IBD vs. Non-IBD Group Native Stool. This figure represents 
the mean Arrowdox ORP of native stool samples for Patients 1-24 in their respective 
disease categories. The mean ORP (mV) of all IBD categories (CD, UC, and IC) was 
decreased compared to control patients. No significant difference was observed between 































ORP of IBD vs. Non-IBD Using Stool Supernatants and Pellets  
Phase Three (January 2021) of the study involved optimizing methods and 
protocols related to ORP measurements. This included measurements of stool 
supernatants collected from fourteen patients using the Arrowdox and Redoxsys 
platforms from January 2021– March 2021. Stool supernatants were obtained using the 
established methods previously outlined. Note that during phase one, stool supernatants 
were measured for Patients 1-7 using the Arrowdox (November 2018 – May 2019), and 
during phase two, stool supernatants of patients 8-14 were measured using the Redoxsys 
(November 2019 – March 2020). The mean of three individual trials from these twenty-
eight patients is represented in Figure 13 and Table 4. Figure 14 represents the disease-
category mean ORP for thirteen patients in which Arrowdox and Redoxsys 
measurements were both obtained. Contemporaneous Arrowdox and Redoxsys 
measurements were not obtained from the initial fourteen patients, and so they were not 
considered in this analysis. In addition, data from Patient 44 was considered an outlier, 
possibly related to collection or storage variability, and eliminated from the analysis. 
Beginning January 2021, the ORP of the stool pellet, obtained through centrifugation, 
was measured using the Arrowdox, and a similar analysis was completed (Figure 15, 
Table 5, Figure 16). 
The results of the pilot stool supernatant analysis suggest that there is a trending 
difference between the ORP measured in the stool supernatants of patients with IBD and 




compared to those measured in Controls.  However the results did not reach statistical 
significance: Arrowdox (p=0.13), Redoxsys (p=0.91). Relative to Control subjects, ORP 
values measured in patients with UC were also more positive when measured using either 
Arrowdox (p=0.17) or Redoxsys (p=0.54) devices.  A single IC stool supernatant sample 
was measured and was decreased in comparison to Control. The results of the pilot stool-
pellet analysis display an inverse relationship between ORP measurement from patients 
with IBD (UC, CD, IC) and Control groups. However, no significant differences were 









Figure 13: The ORP of Stool Supernatant. This figure represents the ORP of stool 
supernatant using the Arrowdox and Redoxsys Device for twenty-eight patients. All 
values are an average of three trials. Patients are labeled under the notation Patient # 
(Disease; PUCAI/PCDAI). All readings were obtained from samples stored at 2°C and 



























































































































































































































































































































































































































































Table 4. ORP (mV) of Stool Supernatant and Patient Diagnoses a   
Patient # (Disease; PUCAI/PCDAI) Arrowdox Redoxsys  
Patient 25 (Crohn's; N/A) 180.333333 180.9 
Patient 26 (Crohn's; N/A) 142.333333 111.866667 
Patient 29 (Crohn's; N/A)  61.3333333 70.6666667 
Patient 32 (Crohn's; 30) 142.333333 67.0333333 
Patient 37 (Crohn's; 0)  50.6666667 75.6333333 
Patient 4 (Crohn's; 15) 22 
 
Patient 6 (Crohn's; 15) 75 
 
Patient 9 (Crohn's; N/A) 
 
185.4 
Patient 45 (Crohn's; N/A) 167.333333 159.2 
Patient 27 (UC; 30) 153.333333 175.1 
Patient 28 (UC; 60) 73 137.866667 
Patient 1 (UC; 10) 183.7 
 
Patient 2 (UC; 45) 114.7 
 
Patient 3 (UC; N/A) 18 
 
Patient 5 (UC; 20) 215 
 
Patient 8 (UC;15) 
 
171.3 
Patient 11 (UC; 30) 
 
151.8 
Patient 13 (UC; 50) 
 
280.033333 
Patient 14 (UC; 30) 
 
180 
Patient 42 (UC; 35) 140.666667 164 
Patient 44 (UC; 60) -385 85.8666667 
Patient 46 (UC; 45) 63.3333333 126.366667 
Patient 38 (IC; N/A) -87.3333333 -119.36667 
Patient 12 (IC; N/A) 
 
147.9 
Patient 34 (Control IBS) -39.3333333 49.4333333 
Patient 10 (Control; N/A) 
 
213.333333 
Patient 41 (Control; Respiratory) 47.3333333 156.3 
Patient 7 (Control; N/A) 218 
 
aThis table lists the ORP (mV) of stool supernatant samples measured using the 





Figure 14: Mean ORP of IBD vs. Non-IBD Group Stool Supernatant. This figure 
represents the mean ORP of stool supernatant for thirteen patients in their respective 
disease categories. Note that Patient 44 was not included in this analysis. UC ORP was 
more positive than Control for the Arrowdox (p=0.17) and Redoxsys (p=0.54) devices. 
CD ORP was more positive than Control for the Arrowdox (p=0.13) and Redoxsys 

















Mean ORP of  IBD vs. Non-IBD 







Figure 15: The ORP of Stool Pellet. This figure represents the ORP of stool pellet 
obtained using the Arrowdox for twelve patients. All values are an average of three trials. 
Patients are labeled under the notation Patient # (Disease; PUCAI/PCDAI). All readings 

























Table 5. ORP (mV) of Stool Pellet and Patient Diagnoses a 
Patient # (Disease; PUCAI/PCDAI) Arrowdox 
Patient 29 (Crohn's; N/A)  -409 
Patient 32 (Crohn's; 30) 118 
Patient 37 (Crohn's; 0)  -157.3333333 
Patient 45 (Crohn's; N/A) -198.33333 
Patient 27 (UC; 30) 26.66666667 
Patient 28 (UC; 60) -11.66666667 
Patient 42 (UC; 35) -384.3333333 
Patient 44 (UC; 60) -461.66667 
Patient 46 (UC; 45) -481 
Patient 38 (IC; N/A) -277 
Patient 34 (Control; IBS) -90 
Patient 41 (Control; Respiratory) -67 






Figure 16: Mean ORP of IBD vs. Non-IBD Group Stool Pellet.  This figure represents 
the mean ORP of stool pellet for eleven patients in their respective disease categories. 
Note that Patient 44 was not included in this analysis. The mean ORP for all IBD (UC, 
CD, IC) groups were decreased in comparison to Control, though not significantly: CD 





























ORP of IBD vs. Non-IBD Using Urine Samples  
During phase three of the study, the implementation of urine analysis was conducted to 
observe if there would be elevated ORP values in patients with IBD. The Redoxsys and 
Arrowdox were the devices used to measure ORP (mV). For each patient, three trials 
were conducted with each device, and the average of the three trials for nineteen patients 
is presented in Figure 17 and Table 6. The mean ORP of urine samples for patients in 
their respective disease categories was calculated and plotted in Figure 18. A direct 
relationship between ORP (mV) and patients suspected of oxidative stress (UC, CD, IC) 












Figure 17: The ORP of Urine. This figure represents the ORP of urine for nineteen 
patients using the Arrowdox and Redoxsys Device. All values are an average of three 
trials. Patients are labeled under the notation Patient # (Disease; PUCAI/PCDAI). Most 
readings were obtained from samples stored at 2°C and measured at an interval between 




















Table 6. ORP (mV) of Urine and Patient Diagnoses a 
Patient # (Disease; PCDAI/PUCAI) Arrowdox Redoxsys  
Patient 25 (CD; N/A) 143.333333 135.166667 
Patient 26 (CD; N/A) 220.333333 174.733333 
Patient 29 (CD; N/A) 141.333333 115.266667 
Patient 31 (CD; N/A ) 198.333333 163.9 
Patient 32 (CD; 30) 173.333333 97.6333333 
Patient 37 (CD; 0) 77 23.6333333 
Patient 45 (CD; N/A) 147 121.7 
Patient 27 (UC; 30) 102.333333 106.633333 
Patient 28 (UC; 60) 161 149.166667 
Patient 44 (UC; 60) 170.333333 152.933333 
Patient 46 (UC; 45) 126.666667 114.966667 
Patient 39 (IC; N/A) 184.333333 169.733333 
Patient 30 (Control; Pancreatitis) 119 100.633333 
Patient 35 (Control; Abd Pain) 107.666667 123.5 
Patient 34 (Control; IBS) 213 150.966667 
Patient 39 (Control; Scoliosis) 81 41.5 
Patient 40 (Control; Sciatica) 149.333333 143.966667 
Patient 43 (Control; Hip) 151 95.6666667 
Patient 47 (Control; Vaginoplasty) 187.666667 167.733333 
aThis table lists the mean ORP (mV) of urine samples measured using the Arrowdox and 





Figure 18: Mean ORP of IBD vs. Non-IBD Group Urine.  This figure represents the 
mean urine ORP for nineteen patients in their respective disease categories. 
Measurements of mean ORP (mV) in the urine of patients with IBD (CD, UC, IC) urine 
samples were not significantly increased compared to Controls for using either the 




































The data collected in this study demonstrates that it may be possible to use fecal 
Oxidative-Reductive Potential (ORP) measurements as a novel biomarker to assess 
disease activity in patients with Inflammatory Bowel Disease (IBD). To establish 
Relative Redox Status (RRS) as a biological marker for IBD, the study was divided into 
several phases. The first phase of the study was a pilot study conducted to demonstrate 
that it is possible to measure ORP in stool samples reliably. It has previously been 
demonstrated that those expected to be experiencing higher oxidative stress (i.e., 
malnutrition subjects, stress-induced exercise subjects) show higher (more positive) 
levels of fecal and blood ORP (mV) values, respectively (Million & Raoult, 2018; Stagos 
et al., 2015). These measurements may be due to a higher level of extracellular reactive 
oxygen and nitrogen species (RONS) concentrations within the gut-fecal and blood 
milieu. 
The devices used in the study were tested against standards and media expected to 
be higher/lower in RONS. These media included juices rich in antioxidants (cranberry, 
apple, orange) as well as H2O2, a well-known endogenous reactive oxygen species 
(Weinbren, 2019; Jie Sun et al., 2002). As expected, diluting antioxidant-rich juices 
produced higher ORP (mV) values, as diluting their concentration alters the balance in 
ambient oxidative and reductive moieties (Stagos et al., 2015). As expected, H2O2 had an 
initial ORP (mV) much higher than the antioxidant juices, and diluting H2O2 decreased 




produce higher ORP values, and diluting their concentration would decrease ORP (mV). 
However, it was not fully understood why a 1:8 dilution of H2O2 increased mV readings. 
This could be the result of technical difficulties or alternation in the chemical stability of 
this over-the-counter product. In conclusion, the precedent was set for measuring the 
ORP of stool samples with the expectation that subjects with more active IBD (UC, CD, 
IC), and thereby experiencing increased intestinal oxidative stress, will have higher (more 
positive) ORP (mV) readings than those without IBD. 
  The initial procurement of fecal ORP values was restricted to real-time (t=0hrs) 
analysis since it was not understood how ORP might change with time. It was unclear 
whether environmental factors, such as exposure to atmospheric oxygen, alter stool ORP. 
To understand how the ORP changes with time and under particular conditions, stool 
ORP was measured under room (20°C), frozen (-80°C), and refrigerated (2°C) 
temperatures at specific time-intervals. It was determined that refrigerated samples up to 
24-hours produced similar ORP values (Figure 9). This greatly facilitated the recruitment 
and collection of samples for this study. 
The second phase of the study involved analyzing native (homogenate) stool 
using two different devices (Arrowdox, PCE). The results of the native stool analysis 
revealed that there were no significant differences in native-stool ORP measurements 
observed between patients with IBD (UC, CD, IC) and without IBD (Figure 14). 
Moreover, patients with IBD displayed ORP (mV) readings that were decreased 




related to the relatively small sample size (only two Control samples were available for 
analysis).  
It was not fully understood why measurements obtained between the Arrowdox, 
PCE, and Redoxsys were discrepant. Theoretically, values taken between devices should 
have yielded comparable results for stool ORP. However, measurements using the PCE 
meter were least consistent. It did not contain an auto-lock setting, and ORP readings 
fluctuated toward more negative values over time.  In response, readings were arbitrarily 
taken when the rate of measurement fluctuation was reduced by subjective inspection. 
When the electrodes from the Model ORP-146S and PCE ORP-14 were switched with 
their respective devices (Lazar Model 6230 and PCE-228-R), the devices' readings were 
similarly altered. Therefore, the measurement discrepancies were not attributed to the 
electronic devices but were more likely related to the individual probes' sensitivity. 
ORP measurement discrepancy between the devices could also have been related 
to different placement in the sample. When thinking about the diverse makeup of RONS 
that explain oxidative stress, it was assumed that different RONS species were uniformly 
distributed in any collected stool samples and that different stool samples contained 
comparable levels of individual RONS species (Kruidenier et al., 2003). If this is, in fact, 
not the case, then changing the placement of a probe in a stool sample may expose an 
electrode to a specific RON and/or RONS environment. Supporting this notion, more 
consistent ORP readings were obtained when measuring liquid samples. Therefore, it was 
determined that future analysis would be based exclusively on measuring the ORP in 




would be eliminated as a measurement device, and the Redoxsys was added to the future-
phase repertoire due to its capability to measure liquid-only samples.   
During the third phase of the study, ORP measurements of stool supernatant and 
pellets were obtained. This poses the question that the presence of specific ROS, or ROS 
in aggregate, may differ when measured in aqueous (supernatant) and solid (pellet) 
samples. Measurement differences may impact this technology's ability to reliably detect 
oxidative stress occurring in the lumen of patients with IBD.  ORP is an integrated 
measure of the balance between total oxidants and total reductants and unknown 
participants (Stagos et al., 2015). Future assessments that address this question are 
necessary. Feces is mostly composed of approximately 75% H2O (Rose et al., 2015). 
Therefore, the assumption was made that polar or charged molecules would distribute 
evenly in the predominantly aqueous stool.  As such, measuring stool supernatants could 
provide a valid assessment of fecal ORP. For the sake of comprehensive analysis, the 
ORP of the pellet was also measured. 
The results of the stool-supernatant analysis revealed that UC and CD groups 
displayed, on average, more positive ORP (mV) values compared to Control patients, 
though not significantly (Figure 14). The Arrowdox displayed more promising results, 
with a higher trend toward increased ORP values.  However, larger sample sizes are 
needed in each group to more confidently determine if the ORP (mV) of stool collected 
from patients with IBD patients is higher (more positive) than those collected in non-IBD 
patients. An essential part of the study was correlating ORP (mV) values to qualitative 




severe disease activity. Therefore, there was an expectation that ORP values would 
directly relate to PUCAI/PCDAI indexes. The correlation was not observed as some 
patients with high or low PUCAI/PCDAI scores presented with either high or low ORP 
values (Table 4).  
Urine analysis was also conducted during the third phase of the study to assess for 
elevated (more positive) ORP values in patients with IBD. However, the data 
demonstrated no differences in the mean ORP of urine from IBD-groups (UC, CD, IC) 
versus Control (Figure 18). It is essential to consider that IBD primarily affects the GI-
system.  It was unclear whether reactive species would be detectable in multiple organ-
systems (i.e., renal and urinary systems). Existing literature suggested that tissue-specific 
RONS production may be reflected by an increased systemic oxidative status (Il’yasova 
et al., 2012). This contributed to an expectation that GI-derived ROS may be filtered and 
therefore detectable (high ORP) in the urine of patients with IBD. The same logic will be 
applied to the future ORP analysis of blood and intestinal aspirates. The chemical 
reactivity of RONS results in their short half-lives.  This fact may make the detection of 
RONS in urine difficult or even improbable. It is also possible that the products of 
oxidative stress, and not the mediators, are detectable in the urine of patients with IBD.  
As such, different technologies may be better suited to make these inquiries.  Most 
samples were measured at 8- to 24-hours post-production. Of note, many urinary 
oxidative-status biomarkers assays measure products of non-enzymatic reactions between 
biological molecules and ROS (i.e., glycation end-products, dityrosine, malondialdehyde, 




antioxidant species are not filtered at the glomerulus at sufficient concentrations to make 
a substantial change in ORP. As such, future studies will focus on time-interval 
experiments that detect how ORP values change over time and under different conditions 
(i.e., 2°C, 20°C, -80°C). 
The data outlined in this manuscript addressed whether there were differences in 
the relative redox status (measured as ORP) in the stool and urine of patients with IBD. 
However, the study did not account for the relative oxidant/antioxidant content of 
enrolled subjects' diets.  These exogenous mediators could confound ORP measurements. 
It has previously been demonstrated that patients on high fat and low fiber diets have 
increased ROS levels in their fecal matter (Erhardt et al., 1997). A comprehensive 
understanding of each patient's diet is necessitated to eliminate variables that may impede 
ORP measurements. The future of the study necessitates surveys on food and 
supplements being taken by each patient. In addition, a comprehensive analysis of 
patient’s gut aerobic and anaerobic bacterial makeup, as well as hemaatochezia 
prevlaence will help to elucidate other confounding RONS. Once a difference between 
the RRS in IBD patients is observed, interventional antioxidant-rich diets will be 









The data gathered during the study suggests that it may be possible to use the 
Oxidative-Reductive Potential (ORP) of stool supernatant as a biological marker for 
Inflammatory Bowel Disease. The initial pilot phases of this study focused on (1) the 
accuracy, reliability, and validity of ORP measurements in stool and (2) the establishment 
of methods that provide consistent intra- and inter-device readings. This ultimately led to 
the measurement of stool supernatant & pellet using the Arrowdox and Redoxsys 
platforms. The next phase of the study will involve amplifying patient recruitment to 
effectively demonstrate a significant difference in stool supernatant ORP in patients with 
IBD. Patient surveys should be utilized to address the possibility of confounding dietary 
factors. Ultimately, measurement of RRS in the stool of patients with IBD could be 
incorporated as an outcome measure in intervention studies, including those involving 
modification in a patient’s diet and/or micro will be implemented to understand if they 
change redox status more favorably.  
Furthermore, since oxidative stress is understood as a systemic status rather than a 
tissue-specific condition, the ORP of urine, intestinal aspirates, and blood will be 
measured. Although the preliminary urinary findings displayed no difference in the ORP 
of samples derived from IBD groups (UC, CD, IC) versus Control, future phases will 
appreciate how urine ORP values change over time. The similarity in urine ORP values 
may be attributed to the short half-life of RONS since most urine was measured 8- to 24-
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